(NASDAQ: GOSS) Gossamer Bio's forecast annual revenue growth rate of 17.93% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.05%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.33%.
Gossamer Bio's revenue in 2026 is $53,286,000.On average, 9 Wall Street analysts forecast GOSS's revenue for 2026 to be $18,017,912,479, with the lowest GOSS revenue forecast at $12,546,739,967, and the highest GOSS revenue forecast at $23,919,270,107. On average, 9 Wall Street analysts forecast GOSS's revenue for 2027 to be $30,399,911,101, with the lowest GOSS revenue forecast at $18,669,545,160, and the highest GOSS revenue forecast at $61,081,397,914.
In 2028, GOSS is forecast to generate $42,705,649,634 in revenue, with the lowest revenue forecast at $10,446,654,449 and the highest revenue forecast at $96,483,677,521.